- Home
- MRM vs LYRA Comparison
MRM vs LYRA Comparison
Compare MRM & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- LYRA
- Stock Information
- Founded
- MRM 2000
- LYRA 2005
- Country
- MRM Japan
- LYRA United States
- Employees
- MRM N/A
- LYRA N/A
- Industry
- MRM Other Consumer Services
- LYRA Medical/Dental Instruments
- Sector
- MRM Consumer Discretionary
- LYRA Health Care
- Exchange
- MRM Nasdaq
- LYRA Nasdaq
- Market Cap
- MRM 12.2M
- LYRA 11.8M
- IPO Year
- MRM 2020
- LYRA 2020
- Fundamental
- Price
- MRM $0.37
- LYRA $0.12
- Analyst Decision
- MRM
- LYRA Hold
- Analyst Count
- MRM 0
- LYRA 4
- Target Price
- MRM N/A
- LYRA $1.25
- AVG Volume (30 Days)
- MRM 1.1M
- LYRA 845.3K
- Earning Date
- MRM 01-01-0001
- LYRA 03-13-2025
- Dividend Yield
- MRM N/A
- LYRA N/A
- EPS Growth
- MRM N/A
- LYRA N/A
- EPS
- MRM N/A
- LYRA N/A
- Revenue
- MRM $44,462,062.00
- LYRA $1,534,000.00
- Revenue This Year
- MRM N/A
- LYRA N/A
- Revenue Next Year
- MRM N/A
- LYRA $519.89
- P/E Ratio
- MRM N/A
- LYRA N/A
- Revenue Growth
- MRM 2.80
- LYRA N/A
- 52 Week Low
- MRM $0.34
- LYRA $0.11
- 52 Week High
- MRM $8.39
- LYRA $5.83
- Technical
- Relative Strength Index (RSI)
- MRM 23.16
- LYRA 21.61
- Support Level
- MRM $0.34
- LYRA $0.14
- Resistance Level
- MRM $0.85
- LYRA $0.20
- Average True Range (ATR)
- MRM 0.06
- LYRA 0.02
- MACD
- MRM -0.00
- LYRA -0.00
- Stochastic Oscillator
- MRM 5.85
- LYRA 5.34
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.